Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Descriptor ID |
D019008
|
MeSH Number(s) |
G07.690.773.984.395
|
Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 1 | 2 | 3 |
1999 | 0 | 4 | 4 |
2000 | 1 | 0 | 1 |
2001 | 0 | 2 | 2 |
2002 | 1 | 8 | 9 |
2003 | 1 | 5 | 6 |
2004 | 2 | 10 | 12 |
2005 | 2 | 6 | 8 |
2006 | 3 | 3 | 6 |
2007 | 5 | 8 | 13 |
2008 | 8 | 9 | 17 |
2009 | 5 | 7 | 12 |
2010 | 8 | 18 | 26 |
2011 | 4 | 11 | 15 |
2012 | 10 | 16 | 26 |
2013 | 10 | 12 | 22 |
2014 | 9 | 15 | 24 |
2015 | 6 | 16 | 22 |
2016 | 12 | 13 | 25 |
2017 | 12 | 20 | 32 |
2018 | 20 | 10 | 30 |
2019 | 13 | 18 | 31 |
2020 | 13 | 15 | 28 |
2021 | 12 | 10 | 22 |
2022 | 2 | 7 | 9 |
2023 | 3 | 5 | 8 |
2024 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence? Cells. 2024 Jul 30; 13(15).
-
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 Jun 25; 8(12):3226-3236.
-
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024 Jun 10; 23(1):121.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681.
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 Apr 23; 8(8):2020-2029.
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
-
5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecol Oncol. 2024 03; 182:82-90.
-
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23):2162-2174.
-
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer. Biomolecules. 2023 10 28; 13(11).